<DOC>
	<DOCNO>NCT00794859</DOCNO>
	<brief_summary>The principal objective study investigate effect sorafenib progression free survival ( time cancer begin grow , ) patient malignant mesothelioma prior treatment chemotherapy . Effectiveness drug also explore PET scan treatment .</brief_summary>
	<brief_title>Sorafenib Previously Treated Malignant Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Malignant pleural peritoneal mesothelioma previously treat first line platinumbased chemotherapy ( prior pemetrexed require ) Not suitable radical resection . Prior radical cytoreductive surgery allow Age &gt; 18 year ECOG performance status 02 Measurable disease . Lesions must measure CT scan MRI accord modify RECIST ( Appendix B ) Life expectancy least 12 week Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior start first dose : haemoglobin ≥ 9.0 g/dL neutrophil count ≥ 1.5 x109/L platelet count ≥ 100 x109/L total bilirubin ≤ 1.5 x upper limit normal ALT AST ≤ 2.5 x upper limit normal ( ≤ 5 x upper limit normal *alkaline phosphatase ≤ 4 x upper limit normal PTINR ( international normalize ratio PT ) / PTT ≤1.5 x upper limit normal Ability understand willingness sign write informed consent . A sign informed consent must obtain prior perform study specific procedure . History cardiac disease : congestive heart failure &gt; NYHA ( New York Heart Association ) class 2 ; active coronary artery disease ( myocardial infarction 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) ; uncontrolled hypertension ( define systolic blood pressure &gt; 150mmHg diastolic pressure &gt; 90mmHg despite optimal medical management ) Impaired immunity chronic infection include history HIV ( human immunodeficiency virus ) infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 NCICTCAE version 3.0 ) Seizure disorder require medication ( steroids antiepileptic ) Known brain metastasis . Patients neurological symptom undergo CT scan/MRI brain exclude brain metastasis History organ allograft Evidence history bleed diathesis coagulopathy ; Renal dialysis Cancer mesothelioma within 5 year prior start study treatment EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumour [ Ta ( noninvasive tumour ) , Tis ( carcinoma situ ) &amp; T1 ( tumour invade lamina propria ) ] Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary haemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug Any haemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first dose study drug Serious , nonhealing wound , ulcer , bone fracture Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate birth control measure course trial . The definition effective contraception base judgment principal investigator designate associate Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardise safety patient compliance study Patients unable swallow oral medication Any malabsorption condition . Any prior systemic anticancer therapy include cytotoxic therapy , target agent , experimental therapy , adjuvant , neoadjuvant therapy malignant mesothelioma , first line platinumbased combination chemotherapy Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow described Prior Concomitant Therapy section ) Major surgery , open biopsy significant traumatic injury within 4 week first dose study drug ( bronchoscopy allow ) Granulocyte colony stimulate factor ( GCSF ) granulocyte macrophage colony stimulate factor ( GMCSF ) , within 3 week study entry Therapeutic anticoagulation vitamin K antagonists warfarin , heparins heparinoids . Low dose warfarin ( 1 mg po OD ) permit INR ( international normalize ratio ) &lt; 1.5 . Lowdose aspirin permit ( ≤ 81 mg daily ) Investigational drug therapy outside trial within 4 week study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>